Zobrazeno 1 - 10
of 923
pro vyhledávání: '"Christoph C, Zielinski"'
Autor:
Angelika Wagner, Erika Garner-Spitzer, Claudia Auer, Pia Gattinger, Ines Zwazl, René Platzer, Maria Orola-Taus, Peter Pichler, Fabian Amman, Andreas Bergthaler, Johannes B. Huppa, Hannes Stockinger, Christoph C. Zielinski, Rudolf Valenta, Michael Kundi, Ursula Wiedermann
Publikováno v:
Vaccines, Vol 12, Iss 5, p 518 (2024)
Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2 vaccination. The effects of booster vaccinations and breakthrou
Externí odkaz:
https://doaj.org/article/26083936ad8646f7a8062db04cd5010d
Autor:
Barbara Kiesewetter, Urania Dafni, Elisabeth G E de Vries, Jorge Barriuso, Giuseppe Curigliano, Veronica González-Calle, Martina Galotti, Bishal Gyawali, Brian Huntly, Ulrich Jaeger, Nicola Jane Latino, Luca Malcovati, Sjoukje Oosting, Gert Ossenkoppele, Martine Piccart, Markus Raderer, Lydia Scarfò, Dario Trapani, Christoph C Zielinski, Ruth Wester, Panagiota Zygoura, Elizabeth Macintyre, Nathan I Cherny
Publikováno v:
HemaSphere, Vol 7, p e02308e3 (2023)
Externí odkaz:
https://doaj.org/article/fbaa6acb8eac44379781acba442210b6
Autor:
Nicholas J. Ede, Anthony J. Good, Joshua Tobias, Erika Garner-Spitzer, Christoph C. Zielinski, Ursula Wiedermann
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Her-2/neu is a tumor-associated protein that is overexpressed in a number of malignancies, including advanced cancer of the stomach, and has been proposed as a human cancer vaccine target. Overexpression of Her-2/neu in human breast and gastric carci
Externí odkaz:
https://doaj.org/article/a32ca5ee9ad244b2a3630daff212e31b
Autor:
Joshua Tobias, Mirjana Drinić, Sandra Högler, Katharina Ambroz, Karin Baier, Petra Kodajova, Erwin Tomasich, Anna S. Berghoff, Anna Schmid, Erika Garner-Spitzer, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Ursula Wiedermann
Publikováno v:
Translational Oncology, Vol 19, Iss , Pp 101378- (2022)
In pre-clinical and clinical settings, active immunization with a Her-2/neu vaccine (HerVaxx), comprising B-cell peptide from Trastuzumab binding site, has been shown to reduce primary tumor growth via induction of polyclonal anti-tumor immune respon
Externí odkaz:
https://doaj.org/article/7d599b48fb6542b08b70ca40b801fdb5
Autor:
Hanna L. Obermeier, Julia Riedl, Cihan Ay, Silvia Koder, Peter Quehenberger, Rupert Bartsch, Alexandra Kaider, Christoph C. Zielinski, Ingrid Pabinger
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 503-514 (2019)
Abstract Essentials Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a highe
Externí odkaz:
https://doaj.org/article/c6bc5c87ba764a30ba94aef60f815d6d
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
Autor:
Joshua Tobias, Claire Battin, Annika De Sousa Linhares, Michael Lebens, Karin Baier, Katharina Ambroz, Mirjana Drinić, Sandra Högler, Aleksandra Inic-Kanada, Erika Garner-Spitzer, Matthias Preusser, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Peter Steinberger, Ursula Wiedermann
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Therapeutic monoclonal antibodies (mAbs), targeting tumor antigens, or immune checkpoints, have demonstrated a remarkable anti-tumor effect against various malignancies. However, high costs for mono- or combination therapies, associated with adverse
Externí odkaz:
https://doaj.org/article/35ad9cad6fd548f381d461c4dd95deb2
Autor:
Daniela Bianconi, Gerwin Heller, Daniel Spies, Merima Herac, Andreas Gleiss, Sandra Liebmann-Reindl, Matthias Unseld, Markus Kieler, Werner Scheithauer, Berthold Streubel, Christoph C. Zielinski, Gerald W. Prager
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Pancreatic cancer is a dismal disease with a mortality rate almost similar to its incidence rate. To date, there are neither validated predictive nor prognostic biomarkers for this lethal disease. Thus, the aim of the present study was to re
Externí odkaz:
https://doaj.org/article/ad7dec37c3fb48049fe3aced16deae55
Autor:
Christoph C Zielinski, Markus Kieler, Matthias Unseld, Daniela Bianconi, Fredrik Waneck, Robert Mader, Fritz Wrba, Thorsten Fuereder, Philipp Staber, Walter Berger, Maria Sibilia, Stephan Polterauer, Leonhard Müllauer, Gerald W Prager
Publikováno v:
ESMO Open, Vol 4, Iss 4 (2019)
Background High-throughput genomic profiling of tumour specimens facilitates the identification of individual actionable mutations which could be used for individualised targeted therapy. This approach is becoming increasingly more common in the clin
Externí odkaz:
https://doaj.org/article/a302d32bee064beda7f655065565cb61
Autor:
Christoph C Zielinski
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 3 (2019)
Externí odkaz:
https://doaj.org/article/dc4afffee342496e810f06ba725e1e04